Literature DB >> 15233941

Restriction of transgene expression to the B-lymphoid progeny of human lentivirally transduced CD34+ cells.

Thomas Moreau1, Florence Bardin, Jean Imbert, Christian Chabannon, Cécile Tonnelle.   

Abstract

Development of gene transfer strategies will necessitate improved efficiency and control of transduction and transgene expression. We here provide evidence that targeting expression of the GFP reporter gene to the B-lymphoid progeny of genetically modified human hematopoietic progenitor cells can be achieved through the insertion of regulatory sequences from the human CD19 gene promoter into a lentiviral vector. Based on a bioinformatics approach, three human CD19-derived sequences were designed and inserted into a self-inactivated lentiviral vector backbone upstream of the GFP gene: S.CD19 (230 bp), M.CD19 (464 bp), and L.CD19 (1274 bp). These new lentiviral vectors efficiently transduced cord blood CD34(+) cells. The M.CD19 and especially L.CD19 sequences preferentially targeted GFP expression to in vitro and in vivo differentiated CD19(+) progeny; moreover, transgene expression was detected from the CD34(+) pro/pre-B cell to the mature peripheral IgM(+) B cell stage. In contrast, GFP expression was weak or absent in primary T-lymphoid and uncommitted progenitor cells or in erythroid, natural killer, or myeloid differentiated cells. Such B-lineage-specific lentiviral vectors may be useful for correcting inherited disorders that affect B-lymphoid cells or for deciphering the transcriptional program that controls B cell commitment and differentiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15233941     DOI: 10.1016/j.ymthe.2004.04.005

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  12 in total

Review 1.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

Review 2.  Engineering humanized mice for improved hematopoietic reconstitution.

Authors:  Adam C Drake; Qingfeng Chen; Jianzhu Chen
Journal:  Cell Mol Immunol       Date:  2012-03-19       Impact factor: 11.530

3.  Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders.

Authors:  Blythe D Sather; Byoung Y Ryu; Brigid V Stirling; Mikhail Garibov; Hannah M Kerns; Stéphanie Humblet-Baron; Alexander Astrakhan; David J Rawlings
Journal:  Mol Ther       Date:  2010-12-07       Impact factor: 11.454

4.  Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.

Authors:  Ilya Leskov; Christian P Pallasch; Adam Drake; Bettina P Iliopoulou; Amanda Souza; Ching-Hung Shen; Carmen D Schweighofer; Lynne Abruzzo; Lukas P Frenzel; Clemens M Wendtner; Michael T Hemann; Jianzhu Chen
Journal:  Oncogene       Date:  2012-04-09       Impact factor: 9.867

5.  In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice.

Authors:  Alessio D Nahmad; Cicera R Lazzarotto; Natalie Zelikson; Talia Kustin; Mary Tenuta; Deli Huang; Inbal Reuveni; Daniel Nataf; Yuval Raviv; Miriam Horovitz-Fried; Iris Dotan; Yaron Carmi; Rina Rosin-Arbesfeld; David Nemazee; James E Voss; Adi Stern; Shengdar Q Tsai; Adi Barzel
Journal:  Nat Biotechnol       Date:  2022-06-09       Impact factor: 68.164

Review 6.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

7.  Targeted gene delivery to CD117-expressing cells in vivo with lentiviral vectors co-displaying stem cell factor and a fusogenic molecule.

Authors:  Steven Froelich; Leslie Ziegler; Katie Stroup; Pin Wang
Journal:  Biotechnol Bioeng       Date:  2009-09-01       Impact factor: 4.530

Review 8.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Authors:  Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

9.  Targeting lentiviral vectors to antigen-specific immunoglobulins.

Authors:  Leslie Ziegler; Lili Yang; Kye il Joo; Haiguang Yang; David Baltimore; Pin Wang
Journal:  Hum Gene Ther       Date:  2008-09       Impact factor: 5.695

Review 10.  Gene therapy for primary immunodeficiencies.

Authors:  Christine Rivat; Giorgia Santilli; H Bobby Gaspar; Adrian J Thrasher
Journal:  Hum Gene Ther       Date:  2012-07       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.